psychedelics investing Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
psychedelics investing Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
psychedelics investing Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
psychedelics investing Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
psychedelics investing Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
psychedelics investing Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026
psychedelics investing Optimi Health Announces Closing of Oversubscribed US$15 Million Public Offering
psychedelics investing Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
psychedelics investing Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026
psychedelics investing Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights
psychedelics investing Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026
